EUVIMEDEUVIMED entdecken
Crossref

Dose escalation of ripretinib can lead to response in advanced gastrointestinal stromal tumor patients refractory to the standard dose: a report of two cases

Philippos Apolinario Costa, Caroline Kamal Abdelmessih Hana, Navin Chakravarthy Balaji, Anthony Frank Skryd, Brianna Nicole Valdes, Ramon O. Minjares, Priscila Barreto-Coelho, Andrea P. Espejo-Freire, Muhammad O. Hakim, Emily Jonczak, Ty Subhawong, Alan Livingstone und 2 weitere

Gastrointestinal Stromal Tumor · 2021

DOI: 10.21037/gist-21-1 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Gastrointestinal Stromal Tumor, 2021. Verfasst von Philippos Apolinario Costa und 13 weiteren Autor:innen. Die Arbeit wurde bisher 4-mal zitiert (Crossref).

AbstractBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Despite an initial response, most metastatic gastrointestinal stromal tumor (GIST) patients will ultimately be refractory to all current therapies, including imatinib, sunitinib, and regorafenib. Ripretinib at 150 mg daily was recently approved as an additional line of treatment. Few options remain after ripretinib. Here we report two cases with responses to dose escalation of ripretinib after progressing on the standard dose. Case 1: A 25-year-old man was diagnosed with a kit exon 9 mutated small intestine GIST after presenting with abdominal pain. The tumor was resected, but a year later, he developed metastases to the liver and pelvis. Over the course of three years, he received multiple lines of therapies as his disease progressed, including imatinib, sunitinib, and regorafenib. He was then placed on ripretinib 150 mg daily. However, he had disease progression after two months. Ripretinib was increased to 150 mg twice a day, which he tolerated well. After three months, he had regression of his disease. Case 2: A 54-year-old male was diagnosed with an unresectable kit exon 11 mutated gastric GISTs after presenting with abdominal pain. Imatinib led to an 80% regression, allowing surgical excision. A year later, his disease recurred. Over the course of 5 years, due to multiple recurrences, he received two additional surgeries, with imatinib, sunitinib, regorafenib, and avapritinib on either the adjuvant or neoadjuvant setting. Ultimately, he developed a metastatic GIST to the left suprarenal region, retroperitoneum, and epigastric region. He was then started on ripretinib 150 mg daily, experiencing progression of his disease in three months. Ripretinib was escalated to 150 mg twice a day, which he tolerated well, and after three months, he had a regression. Dose escalation of ripretinib leads to response in patients that progressed after the standard dose, and it is well-tolerated, being a promising new treatment option in advanced GIST.

Zitieren

APA

Costa, P. A., Hana, C. K. A., Balaji, N. C., Skryd, A. F., Valdes, B. N., Minjares, R. O., Barreto-Coelho, P., Espejo-Freire, A. P., Hakim, M. O., Jonczak, E., Subhawong, T., Livingstone, A., Trent, J. C., & D'Amato, G. Z. (2021). Dose escalation of ripretinib can lead to response in advanced gastrointestinal stromal tumor patients refractory to the standard dose: a report of two cases. Gastrointestinal Stromal Tumor. https://doi.org/10.21037/gist-21-1

Vancouver

Costa PA, Hana CKA, Balaji NC, Skryd AF, Valdes BN, Minjares RO, et al. Dose escalation of ripretinib can lead to response in advanced gastrointestinal stromal tumor patients refractory to the standard dose: a report of two cases. Gastrointestinal Stromal Tumor. 2021. doi:10.21037/gist-21-1

BibTeX
@article{Costa2021,
  author = {Costa, Philippos Apolinario and Hana, Caroline Kamal Abdelmessih and Balaji, Navin Chakravarthy and Skryd, Anthony Frank and Valdes, Brianna Nicole and Minjares, Ramon O. and Barreto-Coelho, Priscila and Espejo-Freire, Andrea P. and Hakim, Muhammad O. and Jonczak, Emily and Subhawong, Ty and Livingstone, Alan and Trent, Jonathan C. and D'Amato, Gina Z.},
  title = {Dose escalation of ripretinib can lead to response in advanced gastrointestinal stromal tumor patients refractory to the standard dose: a report of two cases},
  journal = {Gastrointestinal Stromal Tumor},
  year = {2021},
  doi = {10.21037/gist-21-1}
}
Kostenlos starten →